Listed by the USPTO as SULLIVAN, STEPHANIE LAUREN
Tech Center 1600 • Art Units: 1600 1635 1693
This examiner grants 57% of resolved cases
Sullivan, Stephanie Lauren is assigned to Tech Center 1600 and Art Unit 1600. The record contains 77 resolved cases, with an allowance rate of 57.1%. The profile offers a moderate case history for practitioners assessing how claim presentation and prosecution conduct may relate to outcomes before this examiner.
The interview lift is 38.1%, making interviews an important consideration in prosecution planning based on the reported data. The median time to allowance is 1335 days. The listed companies include Stanford University, the University of Pennsylvania, and Ractigen Therapeutics. The listed firms are STERNE KESSLER, BANNER & WITCOFF, and HOWSON & HOWSON.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18287711 | AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18021901 | DEVELOPMENT OF NOVEL GENE THERAPEUTICS FOR INFLAMMATION-INDUCED BONE LOSS | Non-Final OA | University of Massachusetts |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | Final Rejection | EDITAS MEDICINE, INC. |
| 17627606 | SIRNA SEQUENCES TARGETING THE EXPRESSION OF HUMAN GENES JAK1 OR JAK3 FOR A THERAPEUTIC USE | Final Rejection | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18270014 | Suppression-Replacement Gene Therapy | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18767059 | METHODS AND COMPOSITIONS FOR INHIBITING DETOXIFICATION RESPONSE | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | Final Rejection | The Regents of the University of California |
| 18015102 | NUTRITIONAL COMPOSITION COMPRISING MIR-3141 | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18186290 | IN VITRO GENETIC DISEASE MODEL CELL AND METHOD FOR PRODUCING THE SAME | Final Rejection | RICOH COMPANY, LTD. |
| 18577964 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC PAIN AND FOR RETROGRADE TRANSDUCTION OF NEURONS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18279440 | IN VIVO DNA ASSEMBLY AND ANALYSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18177068 | LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Final Rejection | Vanderbilt University |
| 18283242 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18292521 | HAIRPIN NUCLEIC ACID COMPOSITION | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 17059692 | MODIFIED NUCLEIC ACID INHIBITING MICRO RNA, AND USE THEREOF | Final Rejection | Korea University Research and Business Foundation |
| 17615520 | RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF | Final Rejection | AMGEN INC. |
| 18556944 | COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | Final Rejection | Arrowhead Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.1% of resolved applications examined by Stephanie Lauren Sullivan were allowed (77 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +38.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Stephanie Lauren Sullivan took 1,335 days on average from filing to allowance.
Stephanie Lauren Sullivan examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
